Stryker (NYSE:SYK) recently received FDA clearance for its Incompass® Total Ankle System, a significant product innovation that highlights the company's commitment to advancing patient care. Over the ...

There has been a shift in leadership for the Digital, Robotics and Enabling Technologies business at Stryker (NYSE:SYK).

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Stryker (NYSE:SYK) announced today that it received FDA 510(k) clearance for its Incompass total ankle system.

Stryker received FDA 510(k) clearance for its Incompass® Total Ankle System, intended for patients with severe ...

This has positioned BSX as the second-largest player globally, largely due to the rapid adoption of pulsed field ablation ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our Multi-Factor Investor model based on the published strategy of ...

StrykerSYK saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 64 to 71. Please watch the video at Investors.com - Stock Market Exposure: How To Make ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

America’s new approach to enforcing a decades-old law outlawing foreign bribery means fresh risk for Canadian multinationals, ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.